Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT00527657 | Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients | completed | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 |
| NCT00568763 | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 11 | Mayo ClinicOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | completed | Phase 1 | 4 | Duke UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT01215500 | Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer | completed | Phase 1 | 63 | University of ChicagoOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01608594 | Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | completed | Phase 1 | 30 | Diwakar DavarOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02166255 | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 17 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00074308 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02696356 | Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma | completed | Phase 1 | 18 | BrightPath BiotherapeuticsINDUSTRY | 1 | Jun 14, 2018 | clinicaltrials |
| NCT02138292 | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | completed | Phase 1 | 27 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01893099 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | completed | Phase 1 | 11 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT01943422 | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma(12-107) | completed | Phase 1 | 7 | John KirkwoodOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02668536 | A Sunscreen Based on Bioadhesive Nanoparticles | completed | Phase 1 | 13 | Yale UniversityOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 23 | University Hospital ErlangenOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02613325 | fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01079741 | Safety Study of Adjuvant Vaccine to Treat Melanoma Patients | completed | Phase 1 / Phase 2 | 34 | Nina BhardwajOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01711684 | Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) | completed | Phase 1 | 6 | Rockefeller UniversityOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | completed | Phase 1 | 22 | CelgeneINDUSTRY | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00526617 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | completed | Phase 1 | 41 | AbbVieINDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02441465 | Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies | completed | Phase 1 | 6 | Hoffmann-La RocheINDUSTRY | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00715793 | Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma(UPCI-07-008) | completed | Phase 1 / Phase 2 | 39 | Hussein TawbiOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02574533 | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | completed | Phase 1 | 2 | Gradalis, Inc.INDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00390338 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 22 | Pawel KalinskiOTHER | 1 | Sep 26, 2017 | clinicaltrials |
| NCT01727076 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01622933 | Multiple Antigen-Engineered DC Vaccine for Melanoma | completed | Phase 1 | 35 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT02935790 | Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab | completed | Phase 1 | 1 | CelgeneINDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00405587 | Safety Study of PLX4032 in Patients With Solid Tumors | completed | Phase 1 | 109 | PlexxikonINDUSTRY | 2 | Aug 22, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT02015416 | A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | completed | Phase 1 | 13 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01001299 | A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00062036 | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 33 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00471471 | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 22 | Ahmad TarhiniOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00125749 | Vaccination of Patients With Stage IV Melanoma With Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Baylor Research InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00631072 | In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer | completed | Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT00457418 | High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | completed | Phase 1 | 32 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00658892 | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01496807 | Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | completed | Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01760499 | Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT00940004 | Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients | completed | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01530698 | Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients | completed | Phase 1 / Phase 2 | 28 | Radboud University Medical CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01065467 | Panobinostat (LBH589) in Patients With Metastatic Melanoma | completed | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01844674 | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | completed | Phase 1 | 18 | Hoffmann-La RocheINDUSTRY | 5 | Mar 20, 2017 | clinicaltrials |
| NCT00398073 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01390818 | Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 146 | EMD SeronoINDUSTRY | 3 | Mar 7, 2017 | clinicaltrials |
| NCT00861406 | Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine | completed | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00418496 | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | completed | Phase 1 | 17 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT00553306 | Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01121718 | NIR-Guided Sentinel Lymph Node Mapping in Melanoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 3, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2019source: clinicaltrials